9 Insiders Purchase Shares Of Neptune On Open Market
Article By:
LastFinancier
Read
Tuesday, November 18, 2014 9:30 AM EDT
9 insiders purchased shares of Neptune in the open market during the past week, including the Company’s interim CEO and new Chairman. With activist actions underway, can Neptune stock return to prior levels?
In this article: NEPT
Work Hard And Invest In The Future: Financial Review
Article By:
Marvin R Clark
Read
Monday, November 17, 2014 8:18 PM EDT
If you thought the S&P’s furious 11% rally has been a sight to behold, you clearly weren’t paying attention to the soaring planes, trains and trucks.
Celldex Therapeutics Surges 30% After Positive Phase 2 Data In Brain Cancer
Article By:
Terry Chrisomalis
Read
Monday, November 17, 2014 5:41 PM EDT
Positive results in an interim phase 2 analysis of rindopepimut show increased survival.
In this article: CLDX
View From The Hill: Deflation Shadows Bulls With Disequilibrium In Capital Markets
Article By:
Hillbent
Read
Sunday, November 16, 2014 6:48 PM EDT
Deflation is casting a larger shadow over the U.S. equity bull market and I believe that the Fed may be forced to defer raising rates if the U.S. Dollar continues its upward trajectory while weaker G-8 members (Japan, China, and Europe) maintain highly accommodative policies.
Weighing The Week Ahead: Time To Buy Commodities?
Article By:
Jeff Miller
Read
Sunday, November 16, 2014 9:40 AM EDT
We can expect a normal flow of economic data this week featuring key reports on housing, the FOMC minutes, and the monthly inflation reports. The backdrop for this news includes four additional factors.
Rxi Pharmaceuticals Offers Great Risk-Reward Scenario Before Major Catalysts
Article By:
Terry Chrisomalis
Read
Friday, November 14, 2014 11:05 AM EDT
Rxi Pharmaceuticals is extremely undervalued should approaching catalysts fulfill promise.
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Article By:
The Life Sciences Report
Read
Friday, November 14, 2014 6:49 AM EDT
Mdtech analyst that has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.
CMRX Brincidofovir Selected For Use In Ebola Clinical Trial; AZN And ISIS To Co-Develop Targeted Oligonucleotide Delivery Methods
Article By:
BioMedReports
Read
Friday, November 14, 2014 3:21 AM EDT
CMRX announced its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study with ebola. (ISIS) and (AZN) announced a strategic alliance to develop novel delivery methods for antisense oligonucleotides.
Dynavax May Offer An Opportunity In The Hepatitis B Space
Article By:
Terry Chrisomalis
Read
Thursday, November 13, 2014 5:35 PM EDT
Dynavax's Hepatitis B vaccine Hepislav has the opportunity to bounce back; a first review is positive but there is a ways to go.
In this article: DVAX
Make Stock Picking A Breeze With ROIC
Article By:
David Trainer
Read
Wednesday, November 12, 2014 7:49 PM EDT
Return on Invested Capital “ROIC” is the most dependable indicator to have in your investor toolbox.
Achillion Pharmaceuticals Continues To Impress With Hepatitis C Results In A Combination Study
Article By:
Terry Chrisomalis
Read
Tuesday, November 11, 2014 10:55 AM EDT
ACH-3102 showed 100% Hepatitis C virus clearance in combination with Gilead's sofosbuvir.
ONTY And CLDX Announce Initiation Of Immunotherapy Clinical Trials; NPSP Initiates Study Of Teduglutide
Article By:
BioMedReports
Read
Tuesday, November 11, 2014 3:05 AM EDT
ONTY and CLDX announced they have initiated a combined clinical trial of ONT-10 and varlilumab. NPSP announced the company has initiated a global registration study of teduglutide in pediatric patients.